{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:35:07Z","timestamp":1767652507487},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.pnpbp.2006.08.012","type":"journal-article","created":{"date-parts":[[2006,10,12]],"date-time":"2006-10-12T11:29:39Z","timestamp":1160652579000},"page":"158-163","source":"Crossref","is-referenced-by-count":35,"title":["Quetiapine for the treatment of borderline personality disorder; an open-label study"],"prefix":"10.1016","volume":"31","author":[{"given":"Carmine","family":"Perrella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Carrus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2006.08.012_bib1","author":"American Psychiatric Association"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib2","author":"AstraZeneca"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib4","series-title":"Biological bases of sensation seeking, impulsivity, and anxiety","first-page":"77","article-title":"Impulsivity: cognitive, behavioral, and psychophysiological correlates","author":"Barratt","year":"1983"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.v59n0302","article-title":"Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder","volume":"59","author":"Benedetti","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib6","article-title":"Pharmacological interventions for people with borderline personality disorder","volume":"25","author":"Binks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1034\/j.1399-5618.2002.02229.x","article-title":"Quetiapine in bipolar disorder and cocaine dependence","volume":"4","author":"Brown","year":"2002","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib9","series-title":"Task force for the handbook of psychiatric measures","first-page":"697","article-title":"American Psychiatric Association","author":"Buss","year":"2000"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1037\/0022-3514.63.3.452","article-title":"The Aggression Questionnaire","volume":"63","author":"Buss","year":"1992","journal-title":"J Pers Soc Psychol"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4088\/JCP.v60n0710","article-title":"Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder","volume":"60","author":"Chengappa","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects","volume":"54","author":"Coccaro","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine","volume":"150","author":"Cornelius","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib15","series-title":"Structured clinical interview for DSM-IV AXIS II personality disorders (SCID-II)","author":"First","year":"1997"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib16","series-title":"Structured clinical interview for DSM-IV Axis I disorders","author":"First","year":"1995"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib17","series-title":"Poster presented at the 53rd Annual Meeting of the CPA, Halifax, Novia Scotia, Canada, Oct\u2013Nov","article-title":"Effectiveness of quetiapine for the treatment of aggressive psychosis in the emergency psychiatric setting","author":"Ganesan","year":"2003"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2005-837767","article-title":"Emerging evidence for the use of atypical antipsychotics in borderline personality disorder","volume":"38","author":"Grootens","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/13651500510029048","article-title":"Quetiapine in patients with borderline personality disorder and psychosis: a case series","volume":"9","author":"Gruettert","year":"2005","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib20","unstructured":"Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology \u2014 Revised, Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 218\u2013222."},{"key":"10.1016\/j.pnpbp.2006.08.012_bib21","first-page":"429","article-title":"A rating scale for depression","volume":"133","author":"Hamilton","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0005-7967(97)00064-8","article-title":"A further evaluation of the Aggression Questionnaire: issues of validity and reliability","volume":"35","author":"Harris","year":"1997","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/15622970309167910","article-title":"Quetiapine in the treatment of BPD","volume":"4","author":"Hilger","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.162.3.621","article-title":"Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder","volume":"162","author":"Hollander","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib25","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1345\/aph.1G067","article-title":"Thrombotic thrombocytopenic purpura associated with quetiapine","volume":"39","author":"Huynh","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.151.12.1771","article-title":"Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients","volume":"151","author":"Linehan","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1590\/S1516-44462005000400022","article-title":"Sustained leukopenia probably related to quetiapine","volume":"27","author":"Lobato","year":"2005","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib28","first-page":"773","article-title":"Venlafaxine in the treatment of borderline personality disorder","volume":"31","author":"Markovitz","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib29","first-page":"303","article-title":"Pharmacological treatment of borderline personality disorder","volume":"15","author":"Mazaira","year":"2005","journal-title":"Vertex"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.jcp.0000138763.23482.2a","article-title":"Quetiapine for treatment of alcohol dependence","volume":"24","author":"Monnelly","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib31","first-page":"199","article-title":"Traduzione italiana della Brief Psychiatric Rating Scale, versione 4.0 ampliata (BPRS 4.0)","volume":"3","author":"Morosini","year":"1995","journal-title":"Riv Riabil Psichiatr Psicosoc"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-1913-8","article-title":"Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression","volume":"176","author":"New","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1192\/bjp.168.6.723","article-title":"Severe personality disorders. Treatment issues and selection for in-patient psychotherapy","volume":"168","author":"Norton","year":"1996","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.neuroimage.2004.06.030","article-title":"For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotion","volume":"23","author":"Ochsner","year":"2004","journal-title":"NeuroImage"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00131746-200405000-00003","article-title":"Testing an APA practice guideline: symptom-targeted medication utilization for patients with BPD","volume":"10","author":"Oldham","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/070674370304800116","article-title":"Quetiapine-induced leucopenia: possible dosage-related phenomenon","volume":"48","author":"Oluboka","year":"2003","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2006-931475","article-title":"In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU)","volume":"39","author":"Pessina","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib37","author":"Prescription List"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib38","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","article-title":"SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder","volume":"159","author":"Rinne","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4088\/JCP.v63n0311","article-title":"Treatment of borderline personality disorder with risperidone","volume":"63","author":"Rocca","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1034\/j.1600-0447.2001.00429.x","article-title":"Agranulocytosis and granulocytopenia associated with quetiapine","volume":"104","author":"Ruhe","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":"Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder","volume":"50","author":"Soloff","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-2004-828330","article-title":"Haematological abnormalities during treatment with atypical antipsychotics","volume":"32","author":"Thome","year":"2005","journal-title":"Psychiatr Prax"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1521\/pedi.16.2.113.22547","article-title":"Practice guideline for the treatment of borderline personality disorder: a bridge too far","volume":"16","author":"Tyrer","year":"2002","journal-title":"J Pers Disord"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib47","author":"University of Medicine and Dentistry New Jersey"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib48","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4088\/JCP.v66n1013","article-title":"Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target","volume":"66","author":"Villeneuve","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/10401239409148834","article-title":"Divalproex sodium in the treatment of aggressive behaviour","volume":"6","author":"Wilcox","year":"1994","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0269881105056669","article-title":"The efficacy and safety of quetiapine for treatment of geriatric psychosis","volume":"19","author":"Yang","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.08.012_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1521\/pedi.1989.3.1.10","article-title":"The Revised Diagnostic Interview for Borderlines: discriminating BPD from other axis II disorders","volume":"3","author":"Zanarini","year":"1989","journal-title":"J Pers Disord"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584606003320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584606003320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T17:20:30Z","timestamp":1555867230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584606003320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0278584606003320"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2006.08.012","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}